Biosimilar switch study aims to keep chronic conditions in check
NCT ID NCT07425639
First seen Mar 09, 2026 · Last updated May 23, 2026 · Updated 13 times
Summary
This study follows 225 adults with chronic spontaneous urticaria (long-term hives) or severe allergic asthma whose disease has been stable for at least 3 months on the original omalizumab. Their doctor has decided to switch them to a biosimilar version called Omlyclo®. The main goal is to see if they stay well-controlled or in remission 12 months after the switch, and how satisfied they feel at 6 and 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC ASTHMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Montpellier
RECRUITINGMontpellier, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.